Archive for September, 2013

« Previous Entries

Midlife Sleep Problems Preventable with Sports

Monday, September 30th, 2013

Midlife sleep disturbances among women can be prevented with regular exercise and sports, according to the Study of Women’s Health Across the Nation (SWAN) study. High levels of sports and recreational activity can significantly improve sleep quality, continuity, depth, and efficiency according to the report. The SWAN study also showed that the benefits from these […]

Low Dosage Levels Safer in Hormone Therapies

Monday, September 30th, 2013

Menopausal symptoms, like hot flashes, are often treated with hormone replacement therapy. However, many of these therapies may adversely affect the heart and general health of the patient. A 2002 study done by the Women’s Health Initiative (WHI) showed a link between hormone replacement therapy and increased risk of stroke and heart disease. New research, […]

Loratadine De-scheduling Rejected

Sunday, September 29th, 2013

The Advisory Committee on Medicines Scheduling (ACMS) set up by the TGA recently rejected a move to de-schedule loratidine for use in children between the ages of 6 and 11 years. The TGA recently released documents related to the July meeting held by the Committee. During this meeting, a proposal to move the medication to […]

Lescol has little to Offer for Kidney Disease

Saturday, September 28th, 2013

A recent study indicates that fluvastatin (lescol) and other statins offer little benefit for patients diagnosed with chronic kidney disease patients. They do reduce cholesterol levels, but they do not significantly reduce the frequency of cardiovascular events. These drugs may also trigger severe reactions if they interact with certain other drugs taken by CKD patients. […]

Gabapentin Useful for Pain Intensity Reduction

Friday, September 27th, 2013

A recent study shows that gastro-retentive gabapentin is an effective, safe, and practical treatment option to reduce pain intensity and improve quality of life in patients diagnosed with postherpetic neuralgia (PHN). The study was done by Matthew Clark, MS, and colleagues from the A&A Pain Institute, St. Louis, Missouri. The researchers for this study conducted […]

Asthma and COPD Risk linked to Body Weight

Wednesday, September 25th, 2013

A large-scale Italian study shows a positive link between increasing weight gain to the risk of suffering from asthma or chronic obstructive pulmonary disease (COPD). This association was present independent of smoking history. The study was done by Mario Cazzola and colleagues from the University of Rome Tor Vergata, Italy. A total of 424,889 patients […]

Link between Inflammations and Mania

Tuesday, September 24th, 2013

A recent study shows that inflammation markers are elevated among patients diagnosed with acute mania. The persistent elevation of these markers also predicted the patients’ readmission for acute mania within six months after initial hospitalization. The study was done by Faith Dickerson and colleagues from the Sheppard Pratt Health System, Baltimore. The researchers derive the […]

Weight Loss and CPAP Over Flonase for Sleep Apnea

Monday, September 23rd, 2013

According to the new guidelines published by the American College of Physicians, the first treatment option for obstructive sleep apnea is weight loss. If additional treatment is needed, continuous positive airway pressure or CPAP is the first choice. Mandibular advancement devices can also be considered as an alternative treatment option. The new guidelines by the […]

Effient Offers Little Benefit in Dual Antiplatelet Pretreatment

Sunday, September 22nd, 2013

Non-ST-segment-elevation acute myocardial infarction (NSTEMI) treatment guidelines current recommend dual antiplatelet treatment to begin as early as possible. However, it has been unclear whether early treatment offers any significant benefits, especially with new and more potent antiplatelet agents like prasugrel (Effient). Now, a new study called ACCOAST recently showed strong evidence that pretreatment with prasugrel […]

Cozaar Beneficial in Marfan’s Syndrome Treatment

Sunday, September 22nd, 2013

A recent study suggests that losartan (Cozaar) can help slow down aortic root dilation in patients diagnosed with Marfan’s syndrome. Losartan is an angiotensin receptor blocker, and Marfan’s syndrome is a genetic disorder that affects connective tissue. Aortic dissections are a critical event in Marfan’s syndrome that can often be fatal. The study was done […]

« Previous Entries